New data provides more evidence on choosing the ideal approach for prescription of beta blockers for myocardial infarction.
Hosted on MSN1d
Benefits of complete revascularization confirmed in older patients with ST-elevation myocardial infarctionThe benefits of complete revascularization over culprit-only coronary artery revascularization were confirmed in older ...
A new editorial was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), Volume 16, Issue 16 on August 19, 2024, entitled, "Cardiac metabolism in the ...
"The SENIOR-RITA trial is the largest trial to date in older adults with heart attacks than all previous trials combined.
A new editorial was published in Aging on August 19, 2024, entitled, "Cardiac metabolism in the elderly: effects and ...
Long-term use of beta-blockers in patients with myocardial infarction and preserved heart function does not significantly ...
Quickly cutting non-HDL cholesterol after MI lowers the risk of MACE compared with stepwise use of lipid-lowering therapy.
Since the 1960s, cardiologists have adopted several binary classification systems for acute myocardial infarction (MI) that ...
Most heart attacks are caused by atherosclerosis. Other causes include a blood clot that travels from elsewhere, a spasm, or ...
One statistic that has been particularly vexing, given extensive data showing that cardiovascular medications post–acute ...
No impact was seen on mortality between the invasive and medical arms, but other endpoints may mean more to patients.
NEXLETOL and NEXLIZET are the only non-statins FDA-approved to lower LDL cholesterol and reduce the risk of myocardial infarction and coronary revascularization in primary prevention and secondary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results